Search results for "hormones"

showing 10 items of 1169 documents

Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.

1988

In an effort to overcome possible interference by endogenous gonadotropin-ovarian hormone dynamics, desensitization of the pituitary gonadotropins by a gonadotropin-releasing hormone agonist (GnRHa) was achieved in 12 women with repeatedly failed attempts at multiple follicular stimulation. Eight women were scheduled for in vitro fertilization (IVF) and embryo transfer (ET), and 4 for gamete intrafallopian transfer (GIFT). Stimulation failure was characterized by premature luteinization, poor estradiol (E2) response, or inadequate follicular growth. The agonist was administered by nasal spray 500 to 600 micrograms/day beginning on days 21 to 23 of the menstrual cycle. A rapid desensitizatio…

AgonistAdultendocrine systemmedicine.medical_specialtyMenotropinsmedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilization in VitroBiologyBuserelinReproductive TechniquesOvulation InductionInternal medicineGonadotropin-releasing hormone agonistFollicular phasemedicineHumansGamete intrafallopian transferMenstrual cyclemedia_commonIn vitro fertilisationObstetrics and GynecologyEmbryo TransferEmbryo transferEndocrinologyReproductive MedicineFemaleMenotropinhormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

Structural Mechanism of N-Methyl-D-Aspartate Receptor Type 1 Partial Agonism

2012

N-methyl-D-aspartate (NMDA) receptors belong to a family of ionotropic glutamate receptors that contribute to the signal transmission in the central nervous system. NMDA receptors are heterotetramers that usually consist of two GluN1 and GluN2 monomers. The extracellular ligand-binding domain (LBD) of a monomer is comprised of discontinuous segments that form the functional domains D1 and D2. While the binding of a full agonist glycine to LBD of GluN1 is linked to cleft closure and subsequent ion-channel opening, partial agonists are known to activate the receptor only sub-maximally. Although the crystal structures of the LBD of related GluA2 receptor explain the mechanism for the partial a…

AgonistProtein Structuremedicine.drug_classGlycineMolecular ConformationBiophysicslcsh:MedicineMolecular Dynamics SimulationLigandsta3111Receptors N-Methyl-D-AspartateBiochemistryBiophysics Simulationsta3112Partial agonistIon ChannelsChemical BiologyMacromolecular Structure AnalysismedicineBiomacromolecule-Ligand Interactionslcsh:ScienceReceptorBiologyta116Ion channelCrystallographyMultidisciplinaryChemistrylcsh:Rta1182Glutamate receptorProteinsComputational BiologyNeurotransmittersProtein Structure TertiaryTransmembrane ProteinsBiochemistryCycloserineBiophysicsNMDA receptorLigand-gated ion channellcsh:Qhormones hormone substitutes and hormone antagonistsProtein BindingResearch ArticleNeuroscienceIonotropic effectPLoS ONE
researchProduct

GLP-2: What do we know? What are we going to discover?

2014

Glucagon-like peptide 2 [GLP-2] is a 33-amino acid peptide released from the mucosal enteroendocrine L-cells of the intestine. The actions of GLP-2 are transduced by the GLP-2 receptor [GLP-2R], which is localized in the neurons of the enteric nervous system but not in the intestinal epithelium, indicating an indirect mechanism of action. GLP-2 is well known for its trophic role within the intestine and interest in GLP-2 is now reviving based on the approval of the GLP-2R agonist for treatment of short bowel syndrome [SBS]. Recently it also seems to be involved in glucose homeostasis. The aim of this review is to outline the importance of neuroendocrine peptides, specifically of GLP-2 in th…

Agonistendocrine systemmedicine.medical_specialtyPhysiologymedicine.drug_classClinical BiochemistryEnteroendocrine cellBiologySettore BIO/09 - FisiologiaBiochemistryEnteric Nervous SystemCellular and Molecular NeuroscienceEndocrinologyInternal medicineGlucagon-Like Peptide 2medicineAnimalsHumansGlucose homeostasisReceptorInflammationdigestive oral and skin physiologyShort bowel syndromemedicine.diseaseIntestinal epitheliumGastrointestinal TractEndocrinologyGLP-2 GLP-2 receptor gastrointestinal tract enteric nervous systemEnteric nervous systemGastrointestinal functionNeurosciencehormones hormone substitutes and hormone antagonistsSignal TransductionRegulatory Peptides
researchProduct

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

1999

Previous studies have established the presence of an extrahypothalamic GnRH in a variety of tissues. GnRH receptor is known to be present in the placenta, which produces and secretes the decapeptide from the very early stages of placentation. We hypothesized that GnRH may play a role in the preimplantation development of embryos. To examine this hypothesis, we assessed GnRH and GnRH receptor messenger RNA (mRNA; RT-PCR) and protein expression (Immunohistochemistry) in preimplantation murine embryos at various developmental stages. Furthermore, preimplantation murine embryos were cultured with GnRH agonist and antagonist in vitro to assess the influence of GnRH analogs on embryo development.…

Agonistendocrine systemmedicine.medical_specialtyanimal structuresTranscription Geneticmedicine.drug_classZygoteMice Inbred StrainsGonadotropin-releasing hormoneBiologyMorulaGonadotropin-Releasing HormoneEmbryonic and Fetal DevelopmentMiceEndocrinologyInternal medicinePlacentamedicineAnimalsBlastocystRNA MessengerMessenger RNAReverse Transcriptase Polymerase Chain ReactionEmbryogenesisPlacentationGene Expression Regulation DevelopmentalEmbryoEndocrinologymedicine.anatomical_structureBlastocystembryonic structureshormones hormone substitutes and hormone antagonistsReceptors LHRHEndocrinology
researchProduct

GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome

2012

The GnRH analogue (agonist and antagonist GnRH) changed ovarian stimulation. On the one hand, it improved chances of pregnancy to obtain more oocytes and better embryos. This leads to an ovarian hyper-response, which can be complicated by the ovarian hyperstimulation syndrome (OHSS). On the other hand, the GnRH analogue can prevent the incidence of OHSS: GnRH antagonist protocols, GnRH agonist for triggering final oocyte maturation, either together or separately, coasting, and the GnRH analogue may prove useful for avoiding OHSS in high-risk patients. We review these topics in this article.

Agonistendocrine systemmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismOvarian hyperstimulation syndromeStimulationReview ArticleAndrologyOvarian Hyperstimulation SyndromeInternal medicinemedicineGnRH AntagonistPregnancyGnRH Agonistbusiness.industryPreventionGnRH AntagonistOocytemedicine.diseaseOvarian Stimulationmedicine.anatomical_structureEndocrinologyDisease preventionbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Endocrinology and Metabolism
researchProduct

Personality and Hypothalamic–Pituitary–Adrenal Axis in Older Men and Women

2020

Personality has been related to health and mortality risk, which has created interest in the biological pathways that could explain this relationship. Although a dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been associated with health outcomes and aging, few studies have explored the association between personality and HPA axis functioning in older adults. In addition, it has been suggested that sex could moderate the relationship between personality and HPA axis functioning. Thus, our aim was to analyze the relationship between the big five personality traits and the diurnal cortisol pattern in older adults, as well as sex differences in this relationship. To do so, 7…

Agreeablenessendocrine systemCortisol awakening responsemedia_common.quotation_subjectlcsh:BF1-990050105 experimental psychology03 medical and health sciences0302 clinical medicinemedicinePersonalityPsychology0501 psychology and cognitive sciencesneuroticismhypothalamic–pituitary–adrenal axisBig Five personality traitsconscientiousnessGeneral Psychologyolder adultsmedia_commonOriginal ResearchExtraversion and introversion05 social sciencesConscientiousnessNeuroticismmedicine.anatomical_structurelcsh:PsychologyextraversionPsychology030217 neurology & neurosurgeryHypothalamic–pituitary–adrenal axishormones hormone substitutes and hormone antagonistsClinical psychologyFrontiers in Psychology
researchProduct

Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes.

2011

Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre) with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre(+/-), iDTR(+/-) offspring with DT to selectively destroy the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated Cre(-/-), iDTR(+/-) mice were used as GH-intact controls. AOiGHD im…

Anatomy and PhysiologyMousemedicine.medical_treatmentgh deficiencyMiceEndocrinology0302 clinical medicinefactor-iInsulinglucoseAge of OnsetInsulin-Like Growth Factor I2. Zero hunger0303 health scienceseducation.field_of_studyMultidisciplinarypancreatic beta-cellQRAnimal ModelsGHreceptor genehypothalamic expressionmedicine.anatomical_structureCarbohydrate MetabolismIntercellular Signaling Peptides and ProteinsMedicineincreased insulin sensitivityResearch ArticleHeparin-binding EGF-like Growth Factormedicine.medical_specialtymicediet-induced obesityDisfunción metabólicaSomatotropic cellSciencePopulationEndocrine System030209 endocrinology & metabolismBiologyCarbohydrate metabolismGrowth hormone deficiency03 medical and health sciencesModel OrganismsInsulin resistanceAnterior pituitaryreplacement therapyPituitary Gland AnteriorGrowth FactorsInternal medicinemedicineAnimalsObesityeducationBiologyNutrition030304 developmental biologyDiabetic EndocrinologyEndocrine PhysiologyInsulinDiabetes Mellitus Type 2Metabolyc disfunctionmedicine.diseaseHormonesMice Mutant StrainsSomatotrophsProlactinDietRatsDisease Models AnimalEndocrinologyPituitaryGrowth HormoneInsulin ResistanceEnergy IntakeEnergy MetabolismGHDPLoS ONE
researchProduct

Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications.

2020

: ACE2 receptor has a broad expression pattern in the cellular membrane and provides a protective action against the development of cardiovascular diseases. Recently, this enzyme has become of extreme interest during the pandemic infection of COVID-19 (coronavirus disease 2019). This virus invades alveolar epithelium and cardiomyocytes using ACE2 as a transmembrane receptor. ACE2 is a counter-regulatory peptide that degrades Ang II into Ang 1-7, thereby attenuating the biological effects of the AT1 receptor. The binding between the spike protein of COVID-19 and the enzyme is crucial for the virus to enter the target cells, but whether an increase in ACE2 activity could facilitate the infect…

Angiotensin receptorARDSMyocarditisPneumonia ViralAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPharmacologyPeptidyl-Dipeptidase AVirusSettore MED/11Renin-Angiotensin System03 medical and health sciencesAngiotensin Receptor AntagonistsBetacoronavirus0302 clinical medicinemedicineHumans030212 general & internal medicineReceptorPandemicsDisseminated intravascular coagulationAngiotensin II receptor type 1business.industrySARS-CoV-2COVID-19General MedicineVirus Internalizationmedicine.diseaseCardiovascular DiseasesAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Cardiology and Cardiovascular MedicinebusinessCoronavirus Infectionshormones hormone substitutes and hormone antagonistsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct